Applied Therapeutics, Inc. (APLT)
After hours:
| Previous Close | 1.5200 |
| Open | 1.5400 |
| Bid | 1.4100 x 1300 |
| Ask | 1.4300 x 800 |
| Day's Range | 1.3301 - 1.5400 |
| 52 Week Range | 1.3300 - 25.5900 |
| Volume | |
| Avg. Volume | 239,509 |
| Market Cap | 37.781M |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0020 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.10 |
- Zacks
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
- GlobeNewswire
Applied Therapeutics to Present at the UBS Global Healthcare Conference
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, March 25, 2022 at 10:45 a.m. ET in New York. Webcast information for this event will be accessible on the Events page under the Inv
- Zacks
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
